title: Inflammatory bowel disease therapy: an update.
abstract: The armamentarium for the treatment of IBD has grown considerably within the last decade. Sulfasalazine and corticosteroids, the two cornerstones of past therapy, are now joined by the 5-ASA drugs, antibiotics, immunosuppressive agents, and newer corticosteroids. In addition, several novel therapies with promising initial results are being investigated. As the mechanisms by which these agents work are elucidated, further insight into the pathogenesis of IBD will be gained. Based on the nature and extent of disease, physicians and patients will be able to select the optimal agent or therapeutic combination for control of this enigmatic and morbid disease.
authors.affiliation: Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Shah
authors.forename: M A
authors.initials: MA
authors.lastname: Peppercorn
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D012460:Sulfasalazine / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D007155:Immunologic Factors; D012460:Sulfasalazine